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Abstract
Background—Institutionalized adults are at increased risk of morbidity and mortality from 
influenza and pneumococcal infection. Influenza and pneumococcal vaccination have been shown 
to be effective in reducing hospitalization and deaths due to pneumonia and influenza in this 
population.
Objective—Assess trends in influenza vaccination coverage among U.S. nursing home residents 
from the 2005–06 through 2014–15 influenza seasons and trends in pneumococcal vaccination 
coverage from 2006–2014 among U.S. nursing home residents, by state and demographic 
characteristics.
Methods—Data were analyzed from the Centers for Medicare and Medicaid Services’ (CMS) 
Minimum Data Set (MDS). Influenza and pneumococcal vaccination status were assessed for all 
residents of CMS-certified nursing homes using data reported to the MDS by all certified facilities.
Results—Influenza vaccination coverage increased from 71.4% in the 2005–06 influenza season 
to 75.7% in the 2014–15 influenza season and pneumococcal vaccination coverage increased from 
67.4% in 2006 to 78.4% in 2014. Vaccination coverage varied by state, with influenza vaccination 
coverage ranging from 50.0% to 89.7% in the 2014–15 influenza season and pneumococcal 
vaccination coverage ranging from 55.0% to 89.7% in 2014. Non-Hispanic black and Hispanic 
residents had lower coverage compared with non-Hispanic white residents for both vaccines, and 
these disparities persisted over time.
Conclusion—Influenza and pneumococcal vaccination among U.S. nursing home residents 
remains suboptimal. Nursing home staff should employ strategies such as provider reminders and 
Correspondence and requests for reprints should be sent to: Carla Black, PhD, Immunization Services Division, National Center for 
Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE, Mail Stop A-19, 
Atlanta, GA 30329-4027, zwc0@cdc.gov, Phone: 404-639-8436. 
Disclaimer: The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the 
Centers for Disease Control and Prevention or the Centers for Medicare & Medicaid Services.
Conflicts of interest: none
HHS Public Access
Author manuscript
J Am Med Dir Assoc. Author manuscript; available in PMC 2018 August 01.
Published in final edited form as:
J Am Med Dir Assoc. 2017 August 01; 18(8): 735.e1–735.e14. doi:10.1016/j.jamda.2017.05.002.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
standing orders to facilitate offering vaccination to all residents along with culturally-appropriate 
vaccine promotion to increase vaccination coverage among this vulnerable population.
Keywords
influenza; pneumococcal; vaccination; nursing home
Introduction
Residents of long-term care facilities are at increased risk for hospitalization and death due 
to influenza and pneumonia.1–4 Vaccination with influenza vaccine and 23-valent 
pneumococcal polysaccharide vaccine (PPSV23) have been shown to be effective in 
reducing the incidence of pneumococcal pneumonia and death due to pneumonia and 
influenza in this population.5,6 The Advisory Committee on Immunization Practices (ACIP) 
has recommended annual influenza vaccination for residents of long-term care facilities, 
regardless of age, since 1988.7 While annual influenza vaccination is currently 
recommended for all persons >6 months of age without contraindications for vaccination, 
residents of nursing homes and other long-term care facilities are listed as a group at risk for 
medical complications attributable to severe influenza for whom priority should be given 
when vaccine supply is limited.8 Due to reported outbreaks of pneumococcal disease in 
nursing homes and other long-term care facilities, in 1997 the ACIP recommended that 
pneumococcal vaccination status be assessed for residents of nursing homes and other long-
term-care facilities.9 During 2002 through 2015, published ACIP recommendations 
indicated vaccination of nursing home residents with 23-valent pneumococcal 
polysaccharide vaccine (PPSV23).10,11 In 2016, the recommendation was clarified to 
indicate that nursing home residence alone was not an indication for PPSV23 vaccination for 
adults <65 years; however, these residents should be assessed for pneumococcal vaccination 
status and vaccinated as appropriate based on medical indications.12
A 1996 report by the Institute of Medicine on improving the quality of care in nursing 
homes recommended that all nursing home residents receive periodic standardized 
assessment of their functional, medical, mental, and psychosocial status.13 As a result, 
legislation requiring uniform resident assessment of all nursing home residents was included 
in the Omnibus Budget Reconciliation Act of 1987 (OBRA-87).14 Questions regarding 
influenza and pneumococcal vaccination status were added to the resident assessment 
instrument (RAI) in October 2005, when the Centers for Medicare and Medicaid Services 
(CMS) mandated that all nursing homes offer their residents annual influenza vaccination 
and at least one lifetime pneumococcal vaccination as a condition of certification.15
This paper reports influenza vaccination coverage for the 2005–06 through 2014–15 
influenza seasons and pneumococcal vaccination coverage from 2006–2014 among residents 
of CMS-certified nursing homes.
Methods
The data for this analysis were obtained from the Minimum Data Set (MDS), which is 
maintained by CMS and includes the core set of screening, clinical, and functional status 
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elements collected on the RAI, including immunization assessments. Data collected prior to 
October 1, 2010 were obtained from the MDS version 2.0, and data collected from October 
1, 2010 onward were obtained from the MDS version 3.0.16,17
In accordance with OBRA-87, facilities are required to conduct assessments on all residents 
at admission, quarterly, annually, whenever there is a significant change in the resident’s 
status, and at discharge. The RAI is also used for Medicare Prospective Payment System 
(PPS) assessments to determine payment for Medicare Part A beneficiaries covered under 
the skilled nursing facilities (SNF) benefit. Assessments are conducted for SNF PPS 
residents at 5 days, 14 days, 30 days, 60 days, and 90 days post-admission, and when a 
change in therapy occurs. When the timing of OBRA-87 and SNF PPS assessments 
coincide, one assessment can be used to satisfy both requirements.16,17
Influenza and pneumococcal vaccination status is assessed on the RAI by medical record 
review when possible. If status cannot be determined from the medical record, the resident 
or the resident’s legal guardian is questioned.16,17
Influenza vaccination assessment
The study population for each influenza season included all adults aged ≥18 years in CMS-
certified nursing homes and long-term care facilities who had at least one resident 
assessment of any type (OBRA-87 or SNF PPS) during each influenza season (defined as 
the period from October 1 through March 31 of the next year) during 2005–06 through 
2014–15. While residents must have had at least one assessment during October through 
March to be included in the study population for a given influenza season, all assessments 
from October 1 through June 30 were used to determine vaccination status. The mean 
number of assessments per resident in the study population for each influenza season ranged 
from 4.3 to 5.0. The number of residents included in the study population ranged from 
2,446,647 in 2005–06 to 2,640,219 in 2014–15. Size of the study population for each 
influenza season, by demographic characteristics and by state, are given in Supplemental 
Tables 1–2.
Influenza vaccination status for the 2005–06 through the 2009–10 influenza seasons was 
determined from the following questions in the MDS 2.0: 1) “Did the resident receive the 
Influenza vaccine in this facility for this year’s influenza season (October 1 through March 
31)?”; and 2) “If influenza vaccine not received, state reason.” Influenza vaccination status 
for the 2010–11 through 2014–15 influenza seasons was determined from the following 
questions in the MDS 3.0: 1) “Did the resident receive the influenza vaccine in this facility 
for this year’s influenza season?”; and 2) “If influenza vaccine not received, state reason.” 
Residents with a “yes” response to the first question or a “no” response to the first question 
and response to the second question of “Received outside of this facility” were considered to 
be vaccinated. Residents considered vaccinated on any assessment conducted within an 
influenza season were counted as vaccinated for that season. Sensitivity analyses were 
conducted to examine the effect of excluding residents with discrepant assessments (i.e., 
indicated as vaccinated on one assessment and indicated as unvaccinated in a subsequent 
assessment during the same season) and counting residents with discrepant assessments as 
unvaccinated.
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Residents with missing vaccination information on all assessments conducted within an 
influenza season were excluded from the study population for that season. Residents were 
also excluded from the study population if all assessments for a particular season indicated 
that the resident was unvaccinated and the reason given for non-vaccination was “not present 
in the facility during influenza season”. In total, 2–7% of nursing home residents with 
assessments from October 1 through March 31 were excluded from the study population for 
each influenza season.
Pneumococcal vaccination assessment
The study population for pneumococcal vaccination assessment in each year included all 
adults ≥18 years in CMS-certified nursing homes and long-term care facilities who had at 
least one resident assessment of any type from January 1 through December 31 of each 
calendar year. The mean number of assessments per resident in the study population for each 
year ranged from 4.7 to 5.4. The number of residents included in the study population 
ranged from 3,288,514 in 2006 to 3,786,938 in 2014. Size of the study population for each 
year, by demographic characteristics and by state, are given in Supplemental Tables 3–4.
Pneumococcal vaccination status from assessments conducted prior to October 1, 2010 was 
determined based on the following question in the MDS 2.0: “Is the resident’s PPV status up 
to date?” Pneumococcal vaccination status from assessments conducted from October 1, 
2010 through December 31, 2013 was determined based on the following question in the 
MDS 3.0: “Is the resident’s pneumococcal vaccination up to date?” The definition of “up to 
date” is not given directly on either version of the RAI; however, the RAI 2.0 and RAI 3.0 
user’s manuals specify that vaccination is indicated for residents of nursing homes and other 
long-term care facilities, and revaccination is indicated for those with certain 
immunocompromising conditions and those who received their first dose of pneumococcal 
vaccination before age 65 years.16,17 Residents with a “yes” response on any assessment 
conducted in the calendar year of interest or in any earlier year were considered to be 
vaccinated, regardless of an any subsequent “no” responses. Sensitivity analyses were 
conducted to examine the effect of excluding residents with discrepant assessments (i.e., 
indicated as vaccinated on one assessment and indicated as unvaccinated in a subsequent 
assessment) and counting residents with discrepant assessments as unvaccinated.
Residents were excluded from the study population for a calendar year if pneumococcal 
vaccination information was missing from all assessments conducted during that year and all 
previous years. Three to five percent of residents were excluded from the study population 
each year due to missing information.
Statistical analysis
Descriptive statistics are presented as proportions of residents nationally, by state, and by 
demographic characteristics. Because the study populations for each year or influenza 
season include all eligible residents of CMS-certified nursing homes in the United States, no 
sampling techniques were employed. Multivariable logistic regression was used to determine 
factors independently associated with influenza vaccination in the 2014–15 influenza season 
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and pneumococcal vaccination in 2014. Conditional logit models were used to control for 
facility fixed effects.
Results
Influenza vaccination
Influenza vaccination coverage among U.S. nursing home residents by select demographic 
characteristics is given in Table 1. Influenza vaccination coverage was 75.7% in the 2014–15 
season, an increase of 4.3 percentage points since the 2005–06 influenza season. Vaccination 
coverage in the 2014–15 season decreased 2.7 percentage points from the peak coverage of 
78.4% in the 2009–10 influenza season (while no modification was made to the RAI in 
response to the H1N1 pandemic in 2009–10, providers were instructed by CMS to report 
only seasonal influenza vaccination to the MDS). Coverage increased with increasing age 
and was highest in residents aged ≥85 years in all influenza seasons. Females had higher 
coverage than males in all influenza seasons, with differences ranging from 4.4 percentage 
points in 2005–06 (72.8% compared with 68.4%) to 2.3 percentage points in 2012–13 
(77.5% compared with 75.2%). Among racial/ethnic groups, American Indian/Alaskan 
Native (AI/AN), Asian and Asian or Pacific Islander, and white residents had similar 
coverage across seasons, and had coverage of at least four percentage points higher than 
black and Hispanic residents in all seasons. Across all seasons, coverage among white 
residents was a mean of 7.8 percentage points higher than coverage among black residents. 
The difference in coverage between white and black residents increased from 7.1 percentage 
points in 2005–06 to 9.0 percentage points in 2014–15, when coverage among white 
residents was 77.3% compared with 68.3% among black residents. Residents with chronic 
medical conditions associated with higher risk for influenza-related complications had 
higher coverage compared with residents without high-risk chronic conditions, with 
coverage increasing with increasing number of medical conditions. Widowed residents had 
higher coverage than residents in other marital status groups in all seasons.
State-specific influenza vaccination coverage for the 2005–06 through 2013–14 influenza 
seasons is given in Table 2. Coverage varied by state, ranging from 44.0% to 86.6% in 
2005–06. The variation in coverage persisted across seasons, ranging from 50.0% to 89.7% 
in 2014–15.
In the 2005–06 influenza season, the most commonly reported reason for non-vaccination 
among unvaccinated residents was that the vaccine was not offered (43.8%, Table 3). 
Beginning in 2006–07, the most commonly reported reason for non-vaccination was that the 
resident declined the vaccine (43.2%). This trend continued through the 2014–15 season, 
when 71.9% of unvaccinated residents were offered the vaccine and declined, and 10.6% of 
unvaccinated residents were not offered the vaccine (Table 3). By the 2014–15 influenza 
season, declination of vaccination was the most common reason for non-vaccination among 
residents of all racial/ethnic groups. However, unvaccinated non-white residents were less 
likely to be offered vaccination compared with unvaccinated white residents. In the 2014–15 
influenza season, “not offered” was the reported reason for non-vaccination for 9.8% of 
unvaccinated white residents compared with 14.9%, 14.1%, 14.6%, 13.3%, 12.3%, and 
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14.0% of AI/AN, Asian, Native Hawaiian/Other Pacific Islander, black, Hispanic, and 
residents of multiple races, respectively.
Pneumococcal vaccination
Pneumococcal vaccination coverage in U.S. nursing home residents increased from 67.4% in 
2006 to 79.9% in 2009 (Table 4). Coverage plateaued in 2009, and remained at 
approximately 78–80% from 2009–2014. In all years, coverage increased with increasing 
age and with increasing numbers of chronic medical conditions associated with invasive 
pneumococcal disease. Coverage among females was approximately four percentage points 
higher than coverage among males in all years. In all years from 2006–2014, white residents 
had higher vaccination coverage compared with all other race/ethnicity groups. In 2006, the 
race/ethnicity disparity ranged from 2.7 percentage points difference between white and 
AI/AN residents to 12.9 percentage points difference between white and black residents. 
Racial/ethnic disparities persisted across years, but had narrowed to 1.6 percentage points 
difference between white and AI/AN residents and 8.2 percentage points difference between 
white and black residents in 2014. In 2014, the largest disparity of 9.3 percentage points was 
observed between white and Hispanic residents (coverage of 80.1% versus 70.8%, 
respectively). Widowed residents had higher pneumococcal vaccination coverage than 
residents in other marital status groups in all years.
State-specific pneumococcal vaccination coverage from 2006–2014 is given in Table 5. 
Coverage varied widely by state in all years, ranging from 41.1% to 87.7% in 2006 and from 
55.0% to 89.7% in 2014.
Reasons for non-vaccination among residents who have not received pneumococcal vaccine 
are given in Table 6. In 2006, the most commonly reported reason for non-vaccination was 
that the vaccine was not offered, reported for 49.7% of unvaccinated residents. From 2007–
2014, the most common reason for non-vaccination was that that the resident declined 
vaccination when offered. In 2014, 73.2% of unvaccinated residents were offered and 
declined vaccination. The shift over time from “vaccine not offered” to “vaccine offered and 
declined” as the most common reason for non-vaccination occurred among residents of all 
racial/ethnic groups. However, similar to influenza vaccination, in most years unvaccinated 
non-white residents were less likely to be offered pneumococcal vaccination compared with 
unvaccinated white residents. In 2014, “not offered” was the reported reason for non-
vaccination for 14.6% of unvaccinated white residents compared with 22.4%, 21.0%, 16.9%, 
20.5%, 20.2%, and 16.9% of AI/AN, Asian, Native Hawaiian/Other Pacific Islander, black, 
Hispanic, and residents of multiple races, respectively.
Multivariable analyses
Results of the logistic regression analyses of factors associated with influenza and 
pneumococcal vaccination are given in Table 7. After controlling for other factors (sex, race/
ethnicity, number of chronic medical conditions, and marital status), younger age was 
associated with the lowest odds of vaccination, with younger residents less likely to be 
vaccinated with both influenza and pneumococcal vaccine compared with residents ≥85 
years, and the odds of vaccination decreasing with decreasing age. A similar effect was 
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observed with the number of chronic medical conditions, with residents more likely to be 
vaccinated as number of comorbidities increased. While black residents remained slightly 
less likely than white residents to be vaccinated after controlling for the other factors, the 
differences in coverage between black and white residents with both influenza and 
pneumococcal vaccination decreased after controlling for facility-level fixed effects. 
Hispanic residents were no longer less likely to be vaccinated compared with white residents 
after controlling for the other factors and facility-level fixed effects.
Sensitivity analyses
Results of the sensitivity analysis showed that influenza vaccination coverage in the 2014–
15 season would have been 71.2% if all residents with discrepant assessments were 
considered to be unvaccinated, 74.5% if residents with discrepant assessments were 
excluded from the analysis, and 75.7% if all residents with discrepant assessments were 
considered to be vaccinated (the method used in this report). Pneumococcal vaccination 
coverage in 2014 would have been 66.7% if all residents with discrepant assessments were 
considered to be unvaccinated, 72.0% if residents with discrepant assessments were 
excluded from the analysis, and 78.4% if all residents with discrepant assessments were 
considered to be vaccinated (the method used in this report).
Discussion
Influenza vaccination coverage among U.S. nursing home residents increased from 71.4% in 
the 2005–06 influenza season to 75.7% in the 2014–15 season. This estimate is below the 
Healthy People 2020 (HP2020) target of 90% influenza vaccination coverage among nursing 
home residents.18 Achieving and maintaining high vaccination coverage is important for 
reducing the excess influenza-related morbidity and mortality in this high risk population.
Pneumococcal vaccination coverage among U.S. nursing home residents from the present 
analysis of MDS data was 67.4% in 2006, a substantial increase from a prior report using 
data from the National Nursing Home Survey (NNHS), which reported coverage among 
nursing home residents age ≥65 years of 23.6%-37.4% from 1995–1999.19 Coverage 
continued to increase among residents of all ages from 67.4% in 2006 to 79.9% in 2009. 
Since 2009, coverage has plateaued at approximately 80%, and remains below the HP2020 
target of 90% for pneumococcal vaccination coverage among nursing home residents.18 The 
90% target was met in previous years by five states--Arkansas, Iowa, Minnesota, North 
Dakota, and South Dakota--and reached 89% in several other states. However, in 2014 
coverage had dropped below 90% in all states.
Coverage varied widely by state for influenza and pneumococcal vaccination, with four 
states having coverage below 70% for both vaccinations in the most recent assessment 
periods. Differences in vaccination coverage among nursing home residents by state20 and 
geographic region19,21–22 have consistently been reported in the literature and are likely due 
to factors such as differences between states in immunization policies for both residents and 
health care personnel, differences in state laws regarding nursing home staffing levels,23 
differences in the racial/ethnic distribution of nursing home residents,24 and differences in 
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facility-level characteristics such as bed size, ownership status, and primary payment 
source.19,20–22
Although influenza and pneumococcal vaccination coverage remain suboptimal in many 
states, the shift overall in the reason for non-vaccination for both vaccines from the majority 
of unvaccinated residents not being offered vaccine to the majority of unvaccinated residents 
being offered and declining vaccination is an encouraging finding, suggesting that more 
facilities are now complying with the CMS requirement to offer vaccination to all residents. 
In the most recent years of data collection, the proportion of unvaccinated residents that had 
not been offered influenza or pneumococcal vaccination had been reduced to 10.6% and 
16.0%, respectively. However, the finding that vaccine refusal now plays the largest role in 
residents remaining unvaccinated underscores the need for effective patient education in 
conjunction with access to vaccination. Previous studies have shown that nursing home 
residents were more likely to receive influenza vaccination if they were advised to do so by a 
relative or nursing home health care worker,25 and that coverage increases with more 
frequent physician recommendations.26
Differences in influenza vaccination coverage between white and black nursing home 
residents have previously been reported in assessments conducted in the 2005–06 through 
2008–09 influenza seasons using data from the MDS20,24,27 and in 2003–04 using data from 
the NNHS.28–29 Our analysis revealed that this difference has persisted through the 2014–15 
influenza season, and in fact increased from a difference of 7.1 percentage points higher 
coverage in whites compared with blacks in the 2005–06 season to 9.0 percentage points 
higher coverage in whites in the 2014–15 season. Similarly, differences in pneumococcal 
vaccination coverage between white and black nursing home residents have been reported 
from the NNHS for the years 1995–2004.19,21,28–29 While we found that the difference in 
pneumococcal vaccination coverage between white and black residents was somewhat 
reduced between 2006 and 2014, in 2014 coverage among black residents remained 8.2 
percentage points lower than coverage among white residents.
The vaccination coverage disparity between black and white nursing home residents has 
been attributed in part to the clustering of black residents in what Mor et al. have termed 
“lower-tier” nursing homes, characterized by a greater dependence on Medicaid for payment 
and fewer registered nurses, nurse practitioners and physician assistants, and administrative 
resources per resident compared with upper-tier facilities.19,30–32 The notion that lower 
vaccination coverage among blacks is a result of residence in poorer-quality nursing homes 
is supported by a study by Bardenheier et al. that found that vaccination coverage was lower 
for both blacks and whites in nursing homes with higher proportions of black residents.24 
However, other researchers have found that black residents were less likely to receive 
influenza vaccination than white residents in the same facility and that black residents were 
more likely to refuse vaccination, suggesting that the differences in influenza and 
pneumococcal vaccination coverage between black and white nursing home residents are not 
solely attributable to facility-level characteristics.27 In the current study, the differences in 
vaccination coverage between black and white residents were decreased after controlling for 
clustering of residents within facilities, but facility-level effects did not completely explain 
the differences in coverage. Long-standing differences in both influenza and pneumococcal 
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vaccination coverage have been reported between community-dwelling black and white 
persons ≥65 years, even after adjustment for access to care and other socio-economic 
factors.33–37 These differences have been attributed to resistant attitudes and beliefs about 
vaccination, fewer vaccine-seeking behaviors, poorer provider communication, and less 
effective provider recommendations among blacks.34,38–39 In the current study, while 
vaccine refusal was the most common reason for non-vaccination in white and non-white 
residents, disparities in access to vaccination likely played a role in lower vaccination 
coverage among non-white residents, as these residents were more likely than unvaccinated 
white residents to report not being offered influenza and pneumococcal vaccination.
Little prior research has focused on the disparity between non-Hispanic white and Hispanic 
nursing home residents; however, in the current study, we found differences between non-
Hispanic white and Hispanic residents similar in magnitude to those between non-Hispanic 
white and non-Hispanic black residents for both influenza and pneumococcal vaccination. 
We also found that these differences did not persist after controlling for facility-level effects, 
suggesting the clustering of Hispanics in nursing homes with lower vaccination coverage. 
Lower influenza and pneumococcal vaccination coverage has been reported among 
community-dwelling Hispanics aged ≥65 years compared with their non-Hispanic white 
counterparts.33–35,37,40,41 Unlike non-Hispanic black adults aged ≥65 years, studies have 
found that Hispanics aged ≥65 years were less likely than non-Hispanic whites to report 
resistant attitudes toward vaccination, but more likely to report that they did not know these 
vaccines were recommended for them, suggesting that poor communication or language 
barriers might contribute to lower vaccination coverage in this population.34,38
Influenza and pneumococcal vaccination coverage increased with increasing age and 
increasing numbers of comorbidities among nursing home residents in this study in all 
measurement periods. Increased vaccination coverage with increasing age and increased 
number of high-risk medical conditions is well-documented, both among nursing home 
residents28–29 and community-dwelling persons, even those aged ≥65 years35–36,40–42 due to 
more frequent contacts with medical providers and increased opportunity for vaccination. 
Medical providers might also have increased awareness of age and condition-based 
indications for vaccination. Although less pronounced than differences by age and race/
ethnicity, we found slightly higher influenza and pneumococcal vaccination coverage among 
women and among widowed residents compared with those with other marital statuses. 
However, these differences are likely attributable to higher proportions of older residents in 
these groups.
The findings in this study are subject to several limitations. Vaccination status is reported to 
the MDS by individual facilities. Although the RAI users’ manual outlines the preferred 
procedure for assessing vaccination status, there are no quality checks to ensure that 
assessments are conducted uniformly across facilities. A recent validation study of the 
accuracy of influenza vaccination reported to the MDS found that, overall, influenza 
vaccination coverage measured using RAIs was only 1.8 percentage points lower compared 
to coverage using medical chart review as the gold standard. However, agreement rates 
varied widely by facility and state.43 No such validation study has been published for 
pneumococcal vaccination. Assessment of pneumococcal vaccination status by nursing 
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home staff might be particularly difficult as it is not an annual event like influenza 
vaccination and requires a longer look-back period. Further work to validate pneumococcal 
vaccination data reported to the MDS based on Medicare claims data or medical chart 
review is needed. In the present study, we found disagreement in influenza vaccination status 
between assessments for approximately 5% of residents each influenza season, and 
disagreement in pneumococcal vaccination status for approximately 20% of residents each 
year. Re-vaccination with influenza vaccine is not recommended in the same season. And, 
while adults with certain immunocompromising conditions or those who were initially 
vaccinated prior to age 65 were recommended for re-vaccination with pneumococcal vaccine 
five years after the initial dose, these indications do not explain the high proportion of 
residents in our data who were reported to be vaccinated on one assessment and then 
unvaccinated on a subsequent assessment. These inconsistencies were considered to be 
errors in the subsequent assessments. Higher confidence was placed on earlier assessments, 
because as more time elapsed between the date of vaccination and the date of assessment, 
the likelihood increased that residents or their legal guardians could not recall vaccination 
status or that vaccination in the distant past might not be captured in current medical records. 
Sensitivity analyses revealed that, depending on the handling of these discrepant 
assessments in the analysis, actual influenza and pneumococcal vaccination coverage 
estimates could have been approximately 5% and 10% lower, respectively, than those 
reported in this study.
An additional limitation of the study is that pneumococcal vaccination coverage estimates 
for the year 2014 might not reflect changes in the ACIP recommendation for adults aged ≥65 
years that were published in September 2014. Prior to September 2014, most adults were 
recommended to get one lifetime dose of PPSV23, and the question, “Is the resident’s 
pneumococcal vaccination up to date?” in the MDS 3.0 was most likely interpreted by 
nursing home staff as referring to one dose of PPSV23. Beginning in September 2014, adults 
aged ≥65 years were recommended to receive both 13-valent pneumococcal conjugate 
vaccine (PCV13) and PPSV23, separated by a one-year interval.44 While neither the 
question on the RAI nor the RAI user’s manual were updated to reflect this new 
recommendation, we cannot discount the possibility that personnel completing the 
assessment were aware of the change in the recommendation and considered residents aged 
≥65 who did not have a dose of both PCV13 and PPSV23 as not up to date. However, as this 
change would only affect residents who had their first assessment in September 2014 or 
later, it was not likely to have had a meaningful impact on the coverage estimates in this 
report.
Conclusion
Influenza and pneumococcal vaccination coverage increased among U.S. nursing home 
residents from the 2005–06 through 2014–15 influenza seasons and the years 2006–2014, 
respectively, but remained below national targets of 90% for both vaccines. Non-Hispanic 
black and Hispanic residents were less likely to be vaccinated compared with non-Hispanic 
white residents, and these differences persisted over time. Nursing home administrators 
should employ evidence-based strategies such as standing orders and provider 
reminders45–47 to ensure compliance with the CMS mandate to offer influenza and 
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pneumococcal vaccination to all residents along with culturally-appropriate vaccination 
promotion to increase coverage and protection against disease in this vulnerable population.
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